Infliximab-Related Infusion Reactions: Systematic Review

Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis

(2014) Sun Hyuk Hwang et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

(2014) Filip Baert et al.   Clinical Gastroenterology and Hepatology

Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy)

(2014) Joseph D. Feuerstein et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Reações infusionais imediatas a agentes imunobiológicos endovenosos no tratamento de doenças autoimunes: experiência de 2.126 procedimentos em um centro de infusão não oncológico

(2014) Ingrid Bandeira Moss et al.   Revista Brasileira De Reumatologia

Indications, Protocols, and Outcomes of Drug Desensitizations for Chemotherapy and Monoclonal Antibodies in Adults and Children

(2014) David I. Hong et al.   Journal of Allergy and Clinical Immunology-In Practice

Meta-analysis: rapid infliximab infusions are safe

(2013) H. C. Neef et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

The high-affinity human IgG receptor Fc RI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy

(2013) D. A. Mancardi et al.   BLOOD

Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases

(2013) Payal Saxena et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease

(2013) Sorcha O’Meara et al.   INFLAMMATORY BOWEL DISEASES

World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence Base

(2013) F. Estelle R. Simons et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study

(2013) Abdenour Babouri et al.   Journal of Crohns & Colitis

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

(2013) Kang-Moon Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Variation in Infliximab Administration Practices in the Treatment of Pediatric Inflammatory Bowel Disease

(2013) Jeremy Adler et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Characteristics of anaphylaxis-inducing IgG immune complexes triggering murine passive systemic anaphylaxis

(2012) D. Jiao et al.   ALLERGY

T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study

(2012) Parakkal Deepak et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Genome-wide profiling of bone reveals differentially methylated regions in osteoporosis and osteoarthritis

(2012) Jesús Delgado-Calle et al.   ARTHRITIS AND RHEUMATISM

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Anti-infliximab antibodies in inflammatory bowel disease

(2012) Lennard Y.W. Lee et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Delayed Hypersensitivity Reaction with Infliximab: Unusual to Occur After Initial Dose

(2012) Mazer R. Ally et al.   INFLAMMATORY BOWEL DISEASES

Serum sickness-like reaction due to Infliximab reintroduction during pregnancy

(2012) Anne Grosen et al.   Journal of Crohns & Colitis

The complexity of adverse side-effects to biological agents

(2012) François Aubin et al.   Journal of Crohns & Colitis

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

(2011) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay

(2011) N. Vande Casteele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Tolerability of Shortened Infliximab Infusion Times in Patients With Inflammatory Bowel Diseases: A Single-Center Cohort Study

(2011) Christine Breynaert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management

(2011) Alessandra Vultaggio et al.   Current Opinion in Allergy and Clinical Immunology

Safety of infliximab in 10 years of clinical practice

(2011) Sarah OʼDonnell et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Meta-analysis

(2011) Ziwei Lin et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction

(2011) Alessandra Vultaggio et al.   Internal and Emergency Medicine

Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis

(2011) M. V. Khodoun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis

(2011) F. Estelle R. Simons et al.   World Allergy Organization Journal

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Acute infusion reactions induced by monoclonal antibody therapy

(2010) Enrico Maggi et al.   Expert Review of Clinical Immunology

Safety of infliximab in Crohnʼs disease

(2010) H. Hamzaoglu et al.   INFLAMMATORY BOWEL DISEASES

Infliximab administered with shortened infusion times in a specialized IBD infusion unit: A prospective cohort study

(2010) Gert Van Assche et al.   Journal of Crohns & Colitis

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease

(2010) W. Miehsler et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevention of acute adverse events related to infliximab infusions in pediatric patients

(2010) P. Lahdenne et al.   ARTHRITIS CARE & RESEARCH

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

(2009) G. R. LICHTENSTEIN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice

(2009) Y. ZABANA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions

(2009) A. Vultaggio et al.   ALLERGY

Serum Sickness After Treatment With Rabbit Antithymocyte Globulin in Kidney Transplant Recipients With Previous Rabbit Exposure

(2009) Raghavender Boothpur et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Serum sickness, encephalitis and other complications of anti-cytokine therapy

(2009) Séverine Vermeire et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

(2009) Pál Miheller et al.   BMC GASTROENTEROLOGY

Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis

(2009) Corey A. Siegel et al.   Clinical Gastroenterology and Hepatology

Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment

(2009) Patrick J. Brennan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Infliximab Reintroduction is Not Associated to a Higher Rate of Immune-related Adverse Effects in Patients With Inflammatory Bowel Disease Initially Treated With a Three-infusion Induction Regimen

(2009) Eugeni Domènech et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn’s disease

(2008) A. C. MOSS et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up

(2008) C. W. LEES et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Serious Events with Infliximab in Patients with Inflammatory Bowel Disease

(2008) Hilbert S de Vries et al.   DRUG SAFETY